INTRODUCTION
A meaningful intraocular pressure (IOP) reduction remains the mainstay of current glaucoma management [1] [2] [3] . Although therapy ideally commences with a monotherapy agent, inevitably monotherapies will not suffice for most patients in the long term [3] . Therefore, stepwise medical therapy is often necessary [1, 3] . It has been established, however, that combined antiglaucoma therapy can adversely influence adherence, tolerability, and ocular tissue health [4] [5] [6] . These parameters markedly reduce the success of long-term medical therapy [6, 7] . Treatment advances have been introduced to facilitate the success of combined therapy in real life. For instance, fixed combinations (FCs) were introduced to enhance convenience by minimizing the number of daily drops, improve adherence, enhance tolerability, and conceivably improve long-term ocular outcomes [1, [8] [9] [10] .
In glaucoma a direct consequence of lifelong combined medical therapy is the cumulative toxic effect of preservatives upon and within ocular tissues [10] . The most common preservative contained in glaucoma medications is benzalkonium chloride (BAK), a quaternary ammonium salt that acts as a detergent by disrupting lipid membranes and denaturing proteins [11] . There is convincing scientific evidence to suggest that BAK elicits substantial toxic damage upon the ocular surface [11] [12] [13] [14] . A range of BAK-related ocular surface findings include tear film instability [14, 15] , corneal and conjunctival epithelial apoptosis [15] , increased tear osmolarity [16] , and meibomian gland dysfunction [10] . These signs of ocular surface disease (OSD) cause a variety of ocular symptoms that adversely impact quality of life and ultimately reduce long-term adherence and success of glaucoma therapy [17, 18] . Moreover, chronic exposure to preservatives (especially BAK) may elicit ocular tissue inflammatory and fibrotic reactions that can undermine the potential long-term success of future glaucoma surgery [19] [20] [21] . Lastly, there is growing suspicion that BAK can also damage deeper ocular tissues (e.g., the trabecular meshwork) [10, 22] . Importantly, preservative-related ocular tissue toxicity is cumulative; therefore, patients receiving combined therapies with multiple preserved drops over a long period may be particularly prone to OSD [10] . It is now well documented that the majority of chronically treated glaucoma patients exhibit signs or symptoms of OSD [12] [13] [14] . Simplifying stepwise therapy by employing FCs and switching when possible to preservative-free (PF) medications may ameliorate these toxic effects and enhance the success of long-term stepwise therapy.
Branded or generic latanoprost 0.005% containing BAK is currently the most popular first-choice monotherapy in Europe for patients with ocular hypertension or glaucoma [23] . However since the branded latanoprost formulation contains a high concentration of BAK (0.02%) [24] , there will be, over time, a growing number of patients with signs/ symptoms of OSD. The problem may become more acute when latanoprost-treated patients with signs or symptoms of OSD require adjunctive therapy. Currently there is a paucity of clinical information on the impact upon 24-h IOP efficacy and the comparative ocular surface damage, assessed with validated ocular surface metrics, when we switch patients with signs or symptoms of OSD from preserved latanoprost to a PF medication. Established PF treatment options include tafluprost 0.0015% and dorzolamide 2%/timolol 0.5% fixed combination (DTFC). To the best of our knowledge there is no published evidence on the 24-h efficacy, tolerability, and ocular surface health with the use of a triple PF therapy in glaucoma. Therefore, the main objective of the current study was to evaluate the 24- 
Ocular Surface Assessment
After recording any self-reported ocular surface symptoms, we performed the following tests: 
RESULTS

Patients
Forty-three open-angle glaucoma patients (22 women and 21 men) completed the study out of 45 enrolled (Fig. 1 ). There were 24 patients with exfoliative glaucoma, 18 with primary open-angle glaucoma, and one with pigmentary glaucoma. The mean ± SD age of participants was 66.4 ± 12.3 years. Sixteen patients were using generic latanoprost whereas 27 were using branded latanoprost.
Intraocular Pressure
The mean untreated morning IOP of the study cohort was 30.6 mmHg and the mean 24 An asterisk denotes a statistically significant difference (P\0.001) vs latanoprost baseline. All three ocular surface parameters were also significantly better (P\0.001) with PF tafluprost vs triple PF therapy SD standard deviation 
Adverse Events
All three study regimens were well tolerated ( statistically similar to that seen with triple PF therapy (P = 0.65). Specifically, study subjects reported a significantly greater prevalence of tired eyes (9.3%) or fluctuating vision (9.3%) with preserved latanoprost compared to PF tafluprost (0%) or triple PF therapy (0%) (P = 0.018 for both comparisons; Table 5 ).
Conversely, burning (6.9%), stinging (20.9%), and bitter taste (11.6%) were significantly more common with the triple PF therapy regimen than either latanoprost or tafluprost monotherapies.
DISCUSSION
To the best of our knowledge this is the first study to compare the 24-h efficacy and ocular surface status with a triple PF regimen versus a popular monotherapy: BAK-preserved latanoprost in a cohort of open-angle glaucoma patients. This study also evaluated the same parameters after switching from preserved latanoprost to PF tafluprost monotherapy. It should be noted that all participants were insufficiently controlled on preserved latanoprost monotherapy and also exhibited signs or symptoms of OSD. We opted for a complete 24-h IOP assessment, as previous research has shown conclusively that such studies offer a comprehensive evaluation of the true efficacy of available treatment options [29] [30] [31] [32] .
Lifelong topical antiglaucoma therapy with preserved medications has a detrimental effect on ocular surface health, especially when multiple agents are used. Currently, there is limited controlled evidence pertaining to the health of the ocular surface with chronic combined antiglaucoma therapy [33] . In the present study we employed three easy-to-perform clinical ocular surface metrics: the TFBUT, corneal staining, and the Schirmer test. Although these tests may at times show suboptimal consistency and reliability they are still the mainstay of clinical tests used to detect and quantify epithelial and tear film abnormalities [34] . Owing to the presence of timolol, the additional ocular hypotensive effect was more pronounced during the day than during the night, thus generating a greater fluctuation of treated 24-h IOP. This confirms previously published 24-h evidence [29, 42] that shows that 24-h IOP fluctuation with combined therapy is either the same or slightly worse than that obtained with prostaglandin monotherapies. Moreover, the present study highlights the fact that the true efficacy of PF tafluprost and the triple PF regimen would have remained undetected without a complete 24-h evaluation. Since 24-h monitoring is impractical for the vast majority of glaucoma patients in routine care, we should rely on published controlled 24-h evidence to facilitate management decisions in glaucoma therapy [29] [30] [31] [32] 35] .
A key consideration beyond efficacy in chronic, asymptomatic diseases like glaucoma is the long-term tolerability of glaucoma therapies. Long-term tolerability can affect adherence, efficacy, and ultimately therapeutic success and prognosis. Consequently, the long-term impact of glaucoma medications on ocular surface health should be taken into account in all therapeutic algorithms [6, 10, 13] . In the present trial a similar total number of adverse events was observed with preserved latanoprost and triple PF therapy. In 
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